CA2196304A1 - Controlled local delivery of chemotherapeutic agents for treating solid tumors - Google Patents

Controlled local delivery of chemotherapeutic agents for treating solid tumors

Info

Publication number
CA2196304A1
CA2196304A1 CA002196304A CA2196304A CA2196304A1 CA 2196304 A1 CA2196304 A1 CA 2196304A1 CA 002196304 A CA002196304 A CA 002196304A CA 2196304 A CA2196304 A CA 2196304A CA 2196304 A1 CA2196304 A1 CA 2196304A1
Authority
CA
Canada
Prior art keywords
chemotherapeutic agent
composition
tumor
effective
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002196304A
Other languages
French (fr)
Other versions
CA2196304C (en
Inventor
Henry Brem
Robert S. Langer
Abraham J. Domb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23089835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2196304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2196304A1 publication Critical patent/CA2196304A1/en
Application granted granted Critical
Publication of CA2196304C publication Critical patent/CA2196304C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel, camptothecin, and carboplatin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.

Claims

1. A chemotherapeutic composition comprising a biocompatible polymeric matrix incorporating an effective amount to inhibit tumor growth when released in vivo at the site of the tumor of a relatively water insoluble, relatively lipid insoluble chemotherapeutic agent, wherein the chemotherapeutic agent does not cross the blood-brain barrier in an amount effective to inhibit growth of a solid tumor when administered systemically and is not paclitaxel.
3. The composition of claim 1 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
4. The composition of claim 1 wherein the polymer matrix is biodegradable.
7. The composition of claim 4 wherein the polymeric matrix is formed of a polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, polyproteins and copolymers and blends thereof.
8. The composition of claim 1 wherein the polymeric matrix is formed of ethylene vinyl acetate.
9. The composition of claim 1 further comprising biologically active compounds selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.

10. A method of administering to a patient in need of treatment a relatively water insoluble, relatively lipid insoluble chemotherapeutic agent comprising administering an amount of the chemotherapeutic agent effective to inhibit growth of a solid tumor locally near or in the tumor, wherein the systemic administration of the same dosage of chemotherapeutic agent is not effective to treat tumors and wherein the chemotherapeutic agent does not cross the blood-brain barrier in an amount effective to inhibit growth of a solid tumor when administered systemically and is not paclitaxel.
12. The method of claim 10 wherein the chemotherapeutic agent is camptothecin or a functionally effective derivative.
13. The method of claim 10 wherein the chemotherapeutic agent is locally delivered by direct infusion to the tumor from a reservoir.
14. The method of claim 10 wherein the chemotherapeutic agent is locally delivered by implantation of a biocompatible polymer matrix incorporating the chemotherapeutic agent.
15. The method of claim 14 wherein the polymer matrix is biodegradable.
16. The method of claim 15 wherein the polymeric matrix is formed of a polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, polyphosphazenes, polyorthoesters, polyesters, polyamides, polysaccharides, polyproteins, and copolymers and blends thereof.
17. The method of claim 14 wherein the polymeric matrix is formed of ethylene vinyl acetate.
18. The method of claim 10 further comprising administering radiation in combination with the composition.

19. The method of claim 19 further comprising administering with the chemotherapeutic agent biologically active compounds selected from the group consisting of other chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, anti-angiogenic agents, anti-edema agents, radiosensitizers, and combinations thereof.
20. The method of claim 10 wherein the composition is in the form of micro-implants and are administered by injection or infusion.
CA2196304A 1994-08-02 1995-08-02 Controlled local delivery of chemotherapeutic agents for treating solid tumors Expired - Lifetime CA2196304C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US284,341 1994-08-02
US08/284,341 US5626862A (en) 1994-08-02 1994-08-02 Controlled local delivery of chemotherapeutic agents for treating solid tumors
PCT/US1995/009805 WO1996003984A1 (en) 1994-08-02 1995-08-02 Controlled local delivery of chemotherapeutic agents for treating solid tumors

Publications (2)

Publication Number Publication Date
CA2196304A1 true CA2196304A1 (en) 1996-02-15
CA2196304C CA2196304C (en) 2011-02-15

Family

ID=23089835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2196304A Expired - Lifetime CA2196304C (en) 1994-08-02 1995-08-02 Controlled local delivery of chemotherapeutic agents for treating solid tumors

Country Status (9)

Country Link
US (4) US5626862A (en)
EP (1) EP0774964B1 (en)
JP (1) JPH10505587A (en)
AT (1) ATE290860T1 (en)
CA (1) CA2196304C (en)
DE (1) DE69534080T2 (en)
ES (1) ES2243940T3 (en)
PT (1) PT774964E (en)
WO (1) WO1996003984A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191853B2 (en) 2014-08-15 2021-12-07 The Johns Hopkins University Post-surgical imaging marker

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002647A1 (en) * 1991-10-18 2004-01-01 Ashvin Desai Gel injection treatment of body parts
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
DK1155689T3 (en) * 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogenic stents and methods for their preparation
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
KR100561788B1 (en) * 1996-03-12 2006-09-20 피지-티엑스엘 컴파니,엘.피. Compositions comprising water-soluble paclitaxel prodrugs and implantable medical devices comprising such compositions
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2275438A1 (en) * 1996-11-20 1998-05-28 Board Of Regents, The University Of Texas System Improved methods for transducing cells
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6248362B1 (en) * 1997-03-26 2001-06-19 Meiji Seika Kaisha, Ltd. Large intestinal delivery composite
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
KR20010020432A (en) 1997-04-30 2001-03-15 토마스 씨. 서 Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
NZ525580A (en) * 1997-06-27 2004-08-27 Vivorx Pharmaceuticals Inc Vehicles for intravenous administration of paclitaxel having reduced toxicity
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US6165440A (en) * 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
AU8782098A (en) * 1997-08-13 1999-03-08 Boston Scientific Limited Loading and release of water-insoluble drugs
US20020076442A1 (en) * 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
ES2309258T3 (en) * 1997-10-15 2008-12-16 Polarx Biopharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ARSENIC TRIOXIDE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA.
US6485514B1 (en) 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
DE69926017T2 (en) 1998-04-27 2005-12-22 SurModics, Inc., Eden Prairie Bioactive agents releasing coatings
US6730322B1 (en) 1998-04-30 2004-05-04 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6159143A (en) * 1998-06-17 2000-12-12 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
US6402689B1 (en) * 1998-09-30 2002-06-11 Sicel Technologies, Inc. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
WO2000021370A1 (en) * 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
WO2000029206A1 (en) * 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US20050153926A1 (en) * 1998-12-04 2005-07-14 Adams Christopher P. Method for the immobilization of oligonucleotides
US20020065546A1 (en) * 1998-12-31 2002-05-30 Machan Lindsay S. Stent grafts with bioactive coatings
US20050171594A1 (en) * 1998-12-31 2005-08-04 Angiotech International Ag Stent grafts with bioactive coatings
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
AU782994C (en) * 1999-05-14 2006-08-24 Imclone Llc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
FR2793684B1 (en) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques USE OF BIODEGRADABLE MICROSPHERES RELEASING ANTI-CANCER AGENT FOR THE TREATMENT OF GLIOBLASTOMA, PROCESS FOR PREPARING SUCH MICROSPHERES AND SUSPENSION CONTAINING THEM
KR100844295B1 (en) * 1999-06-04 2008-07-07 알자 코포레이션 Implantable gel compositions and method of manufacture
EP1949890A3 (en) 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6273901B1 (en) 1999-08-10 2001-08-14 Scimed Life Systems, Inc. Thrombosis filter having a surface treatment
CA2385533C (en) 1999-10-04 2008-03-25 Shearwater Corporation Polymer stabilized neuropeptides
JP2003513756A (en) * 1999-11-12 2003-04-15 アンジオテック ファーマシューティカルズ，インコーポレイテッド Compositions of a combination of radiotherapy and a cell cycle inhibitor
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6575888B2 (en) * 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
US6569459B2 (en) 2000-04-10 2003-05-27 Teva Pharmaceutical Industries, Ltd. Method of administration of paclitaxel-plasma protein formulation
CA2406790C (en) 2000-04-19 2009-07-07 Genentech, Inc. Sustained release formulations
US6376525B1 (en) * 2000-09-15 2002-04-23 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
GB0020610D0 (en) * 2000-08-21 2000-10-11 Dytech Corp Ltd Uses of porous carriers
US7524872B2 (en) * 2000-09-15 2009-04-28 Qingzhong Kong Method and composition for treating cancer using cellular organelle crystallizing agents
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US20050054942A1 (en) 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
KR100869824B1 (en) 2000-11-09 2008-11-21 네오팜 인코포레이티드 38 lipid complexes and methods of use
WO2002039112A2 (en) * 2000-11-09 2002-05-16 Sicel Technologies, Inc. In vivo detection of biomolecule concentrations using fluorescent tags
US6514193B2 (en) 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
WO2004026111A2 (en) 2000-11-16 2004-04-01 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US7749539B2 (en) * 2000-11-30 2010-07-06 Efrat Biopolymers Ltd. Polymeric formulations for drug delivery
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US7008642B1 (en) * 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
DE60231862D1 (en) * 2001-02-23 2009-05-20 Genentech Inc ERODABLE POLYMERS FOR INJECTION
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US7011814B2 (en) * 2001-04-23 2006-03-14 Sicel Technologies, Inc. Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject
JP2004529934A (en) * 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド Compositions comprising anti-microtubule agents and polypeptides or polysaccharides, and uses of those compositions for the preparation of a medicament for treating inflammatory conditions
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2004535407A (en) * 2001-05-30 2004-11-25 ターゲサム・インコーポレーテッド Targeted polyvalent polymer
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE386937T1 (en) * 2001-06-19 2008-03-15 Suntory Ltd METHOD FOR ANALYZING A PROTEIN OCCURRING IN THE CELL OR A SUBSTANCE INTERACTING WITH THE PROTEIN
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
AU2002354957A1 (en) * 2001-07-19 2003-03-03 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
US6921390B2 (en) * 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003041684A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
AU2002359407B2 (en) * 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20030091647A1 (en) * 2001-11-15 2003-05-15 Lewis Jennifer A. Controlled dispersion of colloidal suspensions via nanoparticle additions
US7557353B2 (en) * 2001-11-30 2009-07-07 Sicel Technologies, Inc. Single-use external dosimeters for use in radiation therapies
WO2003060799A2 (en) * 2002-01-09 2003-07-24 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
FR2839260B1 (en) * 2002-05-03 2005-02-25 Inst Nat Sante Rech Med MICROPARTICLES BASED ON BICOMPATIBLE AND BIODEGRADABLE MATERIAL SUPPORTING CELLS AND BIOLOGICALLY ACTIVE SUBSTANCES
US20050129776A1 (en) 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
CN100341589C (en) * 2002-05-24 2007-10-10 血管技术国际股份公司 Compositions and methods for coating medical implants
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of buprenorphine
MXPA04011871A (en) * 2002-05-31 2005-07-26 Transmolecular Inc Combination chemotherapy with chlorotoxin.
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (en) 2002-06-25 2005-03-09 Alza Corp SHORT-TERM DEPOSIT FORMULATIONS
CA2491312C (en) * 2002-07-15 2011-05-31 Alcon, Inc. Bioerodible film for ophthalmic drug delivery
US20040013702A1 (en) * 2002-07-16 2004-01-22 Glover Eugene G. Implantable devices for the controlled release of cytotoxic agents
WO2004011054A2 (en) 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
ES2319400T3 (en) * 2002-07-31 2009-05-07 Durect Corporation COMPOSITIONS INJECTABLE DEPOSIT AND USE OF THE SAME.
US20080260834A1 (en) * 2002-08-20 2008-10-23 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
KR20040017002A (en) * 2002-08-20 2004-02-26 한국화학연구원 Locally implantable pharmaceutical preparation of anticancer agent containing osmotic agent
US20040226620A1 (en) * 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
CN100366249C (en) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 Control releasing administration system for temozolomide
EP1581181B1 (en) * 2002-11-06 2008-12-24 ALZA Corporation Controlled release depot formulations
US7053125B2 (en) * 2002-11-14 2006-05-30 The Board Of Trustees Of The University Of Illinois Controlled dispersion of colloidal suspension by comb polymers
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
CN104587479A (en) 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 Compositions and methods of delivery of pharmacological agents
CN1732022A (en) * 2002-12-30 2006-02-08 血管技术国际股份公司 Silk stent grafts
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
US20040197301A1 (en) * 2003-02-18 2004-10-07 Zhong Zhao Hybrid polymers and methods of making the same
AU2004214420A1 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
DK1610791T3 (en) 2003-03-31 2011-05-09 Titan Pharmaceuticals Inc Implantable polymer dopamine agonist sustained release device
EP1620002B1 (en) * 2003-04-24 2012-01-04 The Board Of Regents, The University Of Texas System Noninvasive blood analysis by optical probing of the veins under the tongue
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
JP4824549B2 (en) 2003-05-02 2011-11-30 サーモディクス，インコーポレイティド Controlled release bioactive substance delivery device
EP1643968A1 (en) * 2003-05-30 2006-04-12 ALZA Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US7141617B2 (en) * 2003-06-17 2006-11-28 The Board Of Trustees Of The University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7226622B2 (en) 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
WO2005039537A1 (en) 2003-10-22 2005-05-06 Lidds Ab Composition comprising biodegradable hydrating ceramics for controlled drug delivery
US7413690B1 (en) * 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
WO2005046747A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050124941A1 (en) * 2003-11-14 2005-06-09 Martin Panchula Package for pharmaceutical formulation
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
JP4734319B2 (en) * 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー Human anti-epidermal growth factor receptor antibody
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
JP4433918B2 (en) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 Image forming method
EP3417895A1 (en) 2004-07-28 2018-12-26 Medtronic Ardian Luxembourg S.à.r.l. Methods and devices for renal nerve blocking
US8541028B2 (en) * 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
ES2531425T3 (en) 2004-10-05 2015-03-13 Genzyme Corp Staggered cannula
US20060093639A1 (en) * 2004-10-29 2006-05-04 Starkebaum Warren L Method and device for destroying body tissue
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
KR100651728B1 (en) * 2004-11-10 2006-12-06 한국전자통신연구원 Compounds having anchoring group and electronic device including the same and methods for producing the same
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
ATE531365T1 (en) 2005-02-18 2011-11-15 Abraxis Bioscience Llc COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20060216327A1 (en) * 2005-03-28 2006-09-28 Bacterin, Inc. Multilayer coating for releasing biologically-active agents and method of making
US8574259B2 (en) * 2005-05-10 2013-11-05 Lifescreen Sciences Llc Intravascular filter with drug reservoir
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011802A1 (en) 2005-07-18 2007-01-25 Nektar Therapeutics Al, Corporation Method for preparing branched functionalized polymers using branched polyol cores
US8187159B2 (en) 2005-07-22 2012-05-29 Biocompatibles, UK Therapeutic member including a rail used in brachytherapy and other radiation therapy
US7736293B2 (en) 2005-07-22 2010-06-15 Biocompatibles Uk Limited Implants for use in brachytherapy and other radiation therapy that resist migration and rotation
US9101949B2 (en) * 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US20070031611A1 (en) * 2005-08-04 2007-02-08 Babaev Eilaz P Ultrasound medical stent coating method and device
ES2556974T3 (en) * 2005-08-12 2016-01-21 Jiang Liu Devices for lymphatic system orientation
US7896539B2 (en) * 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
CA2619882C (en) * 2005-08-23 2015-05-26 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
US8060181B2 (en) * 2006-04-07 2011-11-15 Brainlab Ag Risk assessment for planned trajectories
EP1844725B1 (en) 2006-04-07 2009-03-25 BrainLAB AG Risk assessment for planned trajectories
EP2012815A4 (en) * 2006-04-14 2009-12-09 Massachusetts Inst Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
SI2019683T2 (en) 2006-04-25 2022-10-28 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
ES2540059T3 (en) 2006-04-26 2015-07-08 Micell Technologies, Inc. Coatings containing multiple drugs
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US8754045B2 (en) * 2006-05-12 2014-06-17 James A. Livingston Enzymatic debridement therapy for abnormal cell proliferation
US8066824B2 (en) * 2006-07-07 2011-11-29 Intezyne Technologies, Inc. Covalent modification of metal surfaces
CN101138634A (en) * 2006-09-07 2008-03-12 于保法 Composition for treating tumour
US20090169628A1 (en) * 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
WO2008052000A2 (en) 2006-10-23 2008-05-02 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20080142616A1 (en) * 2006-12-15 2008-06-19 Bacoustics Llc Method of Producing a Directed Spray
US9737642B2 (en) * 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2136853B1 (en) 2007-01-21 2013-04-10 Hemoteq AG Medical product for treating stenosis of body passages and for preventing threatening restenosis
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
US7669883B2 (en) * 2007-03-29 2010-03-02 Newfrey Llc Air bag bracket/fastener
US7956102B2 (en) * 2007-04-09 2011-06-07 The Board Of Trustees Of The University Of Illinois Sol-gel inks
KR101187628B1 (en) * 2007-05-17 2012-10-05 메드제네시스 테라퓨틱스 인코포레이티드 Convection-enhanced delivery catheter with removable stiffening member and method for using same
WO2008148013A1 (en) 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
WO2009088777A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US20110052580A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
CA2755014A1 (en) * 2008-03-10 2009-09-17 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
SG192524A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8815232B2 (en) * 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
WO2010037021A2 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
CN102202646A (en) * 2008-09-30 2011-09-28 Endo药物方法有限公司 Implantable device for the delivery of risperidone and methods of use thereof
US7922939B2 (en) * 2008-10-03 2011-04-12 The Board Of Trustees Of The University Of Illinois Metal nanoparticle inks
US8187500B2 (en) * 2008-10-17 2012-05-29 The Board Of Trustees Of The University Of Illinois Biphasic inks
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc Drug delivery medical device
EA201171195A8 (en) * 2009-03-30 2014-08-29 Серулин Фарма Инк. CONJUGATES, PARTICLES, POLYMER-AGENT COMPOSITIONS AND METHODS OF THEIR APPLICATION
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
WO2010124098A2 (en) * 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of drug polymorphs to achieve controlled drug delivery from a coated medical device
WO2010132763A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
EP3064230B1 (en) * 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
JP5933434B2 (en) * 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． Method for producing drug delivery balloon
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
ES2522167T3 (en) * 2010-01-05 2014-11-13 National Dong Hwa University Anti-cancer formulation
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
WO2011097103A1 (en) * 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
KR101923235B1 (en) 2010-02-04 2018-11-28 에이자이 아이엔씨. Chlorotoxin polypeptides and conjugates and uses thereof
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
PL2552415T3 (en) 2010-03-29 2017-03-31 Abraxis Bioscience, Llc Methods of treating cancer
CN105147613A (en) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 Methods of enhancing drug delivery and effectiveness of therapeutic agents
EP2558154B1 (en) 2010-04-16 2020-06-17 ClearPoint Neuro, Inc. Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
AU2011253424B2 (en) 2010-05-11 2016-02-04 Fred Hutchinson Cancer Center Chlorotoxin variants, conjugates, and methods for their use
US8383405B2 (en) 2010-05-31 2013-02-26 Imperium Biotechnologies, Inc. Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
US8518409B2 (en) 2010-05-31 2013-08-27 Imperium Biotechnologies, Inc. System for selective cell treatment using ideotypically modulated pharmacoeffectors
MY162903A (en) 2010-06-04 2017-07-31 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
EP2392546A1 (en) 2010-06-07 2011-12-07 Centre National de la Recherche Scientifique (CNRS) Solutions of carbon nanohorns, method for making same and uses thereof
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
EP3449856B1 (en) 2010-10-25 2023-06-28 Medtronic Ardian Luxembourg S.à.r.l. Device for evaluation and feedback of neuromodulation treatment
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
TW201323011A (en) * 2011-10-24 2013-06-16 Endo Pharmaceuticals Solutions Implantable rasagiline compositions and methods of treatment thereof
WO2013124869A2 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
AU2013229776B2 (en) 2012-03-08 2016-12-15 Medtronic Af Luxembourg S.A.R.L. Biomarker sampling in the context of neuromodulation devices and associated systems
WO2013134548A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
CA2874824C (en) 2012-06-01 2021-10-26 Surmodics, Inc. Apparatus and methods for coating balloon catheters
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
CA2913127A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
WO2014165264A1 (en) 2013-03-12 2014-10-09 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
EP3223810A1 (en) 2014-11-26 2017-10-04 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
US10774176B2 (en) 2014-12-18 2020-09-15 Dexcel Pharma Technologies Ltd. Alternating and semi-alternating poly(ester-anhydride) copolymers
US11291646B2 (en) 2015-06-04 2022-04-05 Crititech, Inc. Nozzle assembly and methods for use
EP3310343B1 (en) 2015-06-18 2023-05-24 Acuitybio Corporation Implantable drug delivery compositions and methods of use thereof
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
CA3018989A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
CZ2016804A3 (en) * 2016-12-16 2018-04-18 Synthesia, A. S. A supramolecular complex of an oxycellulose matrix with a taxol derivative with sequential release of the taxol derivative and its use
US11141488B2 (en) 2017-03-29 2021-10-12 Dexcel Pharma Technologies Ltd. Compositions comprising biodegradable copolymers for prolonged local release of an antibiotic
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
SG10201913400QA (en) 2017-06-14 2020-03-30 Crititech Inc Methods for treating lung disorders
JP2020536052A (en) 2017-10-03 2020-12-10 クリティテック・インコーポレイテッド Topical delivery of antitumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
EP3781074A1 (en) 2018-05-09 2021-02-24 ClearPoint Neuro, Inc. Mri compatible intrabody fluid transfer systems and related devices and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CA3087410A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
MX2020014160A (en) * 2018-06-25 2021-03-09 Titan Pharmaceuticals Inc Implants for release of lipophilic or amphiphilic pharmaceutical substances.
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3991766A (en) 1973-05-31 1976-11-16 American Cyanamid Company Controlled release of medicaments using polymers from glycolic acid
US3976071A (en) 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4076798A (en) 1975-05-29 1978-02-28 American Cyanamid Company High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
US4328204A (en) 1977-03-02 1982-05-04 Ethicon, Inc. Absorbable polymer-drug compounds and method for making same
US4322323A (en) 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4346709A (en) 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US5248700A (en) 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4888176A (en) * 1984-05-21 1989-12-19 Massachusetts Institute Of Technology Controlled drug delivery high molecular weight polyanhydrides
US5286763A (en) 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JP2551756B2 (en) 1985-05-07 1996-11-06 武田薬品工業株式会社 Polyoxycarboxylic acid ester and method for producing the same
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
IL78826A (en) 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4789724A (en) * 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
DE3710175A1 (en) 1987-02-12 1988-08-25 Hoechst Ag MULTI-PIECE IMPLANTABLE MEDICINE PREPARATION WITH LONG-TERM EFFECT
US4867978A (en) * 1987-03-27 1989-09-19 Joseph Gold Method of prolonging cancerous patient survival in humans with hydrazine sulfate
US5114719A (en) 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
FR2618674B1 (en) 1987-07-30 1990-06-15 Ire Celltarg Sa MICROPARTICLES COMPRISING A BIODEGRADABLE POLYMER CONTROLLING THE RELEASE OF AN ANTIMALARIA ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHOD OF PREPARATION
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
WO1989002374A1 (en) 1987-09-15 1989-03-23 Cambon Pty. Ltd. Trailer control
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5187150A (en) 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
DE68901931T2 (en) 1988-02-11 1992-12-10 Matrix Pharma COMPOSITIONS FOR TREATING BRAIN TUMORS.
JP2670680B2 (en) 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US4975526A (en) 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5356630A (en) 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US4999417A (en) 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US5122367A (en) 1989-03-31 1992-06-16 Massachusetts Institute Of Technology Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone
US5108755A (en) 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US4997904A (en) 1989-08-25 1991-03-05 Nova Pharmaceutical Corporation Aromatic polyanhydride compositions
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
EP0423484B1 (en) 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Tablet with sustained release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US5171812A (en) 1990-01-19 1992-12-15 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
US5175235A (en) 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
US5240963A (en) 1990-01-19 1993-08-31 Nova Pharmaceutical Corporation Branched polyanhydrides
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5328698A (en) 1990-08-06 1994-07-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic and/or anti-infective
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
NO302481B1 (en) 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for an extended release preparation, as well as an extended release preparation
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HU222501B1 (en) 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5211951A (en) 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5302397A (en) 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5281419A (en) 1992-09-28 1994-01-25 Thomas Jefferson University Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
DE69431071T2 (en) 1993-12-29 2003-03-20 Matrix Pharma COMPOSITION FOR LOCAL RELEASE OF CYTOSTATICS
US5395850A (en) * 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191853B2 (en) 2014-08-15 2021-12-07 The Johns Hopkins University Post-surgical imaging marker

Also Published As

Publication number Publication date
WO1996003984A1 (en) 1996-02-15
DE69534080T2 (en) 2006-04-13
US5651986A (en) 1997-07-29
ATE290860T1 (en) 2005-04-15
JPH10505587A (en) 1998-06-02
DE69534080D1 (en) 2005-04-21
US5846565A (en) 1998-12-08
EP0774964B1 (en) 2005-03-16
CA2196304C (en) 2011-02-15
US5626862A (en) 1997-05-06
USRE37410E1 (en) 2001-10-16
EP0774964A1 (en) 1997-05-28
ES2243940T3 (en) 2005-12-01
PT774964E (en) 2005-08-31

Similar Documents

Publication Publication Date Title
CA2196304A1 (en) Controlled local delivery of chemotherapeutic agents for treating solid tumors
EP2244752B1 (en) Low viscosity liquid polymeric delivery system
US20040013702A1 (en) Implantable devices for the controlled release of cytotoxic agents
US20010046961A1 (en) Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
WO2006080951A3 (en) Targeted and high density drug loaded polymeric materials
Buahin et al. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release
JP2001502331A (en) Cytokine-enhanced immunotherapy for brain tumors
US20020041888A1 (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
Domb Polymericcarriers for regional drug therapy
Yapp et al. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin
US5637085A (en) Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
Okumu et al. Implants and injectables
US20040224000A1 (en) Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
US6569459B2 (en) Method of administration of paclitaxel-plasma protein formulation
EP1827377B1 (en) In-situ forming implant for animals
US20050266076A1 (en) Resorbable delivery systems for the treatment of cancer
Bharad et al. IMPLANTABLE DRUG DELIVERY SYSTEMS: AN UPDATED REVIEW.
Cherrv et al. Comparison of intermittent bolus with continuous infusion of epidural morphine in the treatment of cancer pain
KR20030005997A (en) Controlled delivery of locally implantable chemotherapeutic agent for treating brain tumor
Noorduin et al. Clinical experience with epidural sufentanil
Domb et al. Biodegradable polymers for cancer therapy
Pawar et al. 17 Injectable Polymers for Regional Drug Delivery
WO2001000240A2 (en) Antitumor compound
WO2004050100A1 (en) Method for treating a tumor using a thermo-gelling chitosan composition

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150803